<DOC>
	<DOCNO>NCT01498640</DOCNO>
	<brief_summary>The objective study assess safety efficacy AA4500 retreatment recurrent contractures joint effectively treat AA4500 previous Auxilium-sponsored Phase 3 study .</brief_summary>
	<brief_title>Retreatment Recurrent Dupuytren 's Contractures</brief_title>
	<detailed_description>Open-label , Phase 4 study subject currently participate long-term follow-up study ( ie , AUX-CC-860 ) United States , Australia , Europe recurrence contracture ( ie , joint contracture increase least 20 degree compare Day 30 value last injection Phase 3 Auxilium-sponsored study palpable cord present ) joint effectively treat ( ie , reduction contracture 5 degree less 30 day last injection ) AA4500 Phase 3 Auxilium-sponsored study . Subjects experience recurrence contracture one effectively treated joint may enrol retreatment study investigator determines subject eligibility inform consent obtain . The investigator treat cord affect recurrent joint three injection . Only one recurrent joint treat study .</detailed_description>
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>1 . Provide write informed consent 2 . Be currently participate AUXCC860 followup study 3 . Have least one joint following : The joint effectively treat ( correction 5 degree less Day 30 evaluation last injection AA4500 ) previous Auxilium Phase 3 study The effectively treat joint increase contracture least 20 degree compare Day 30 value last injection AA4500 previous Auxilium Phase 3 study A palpable cord present joint treat 4 . Be able comply study visit schedule specify protocol 1 . Is pregnant lactate female female intend become pregnant study 2 . Has hypersensitivity AA4500 AA4500 excipients 3 . Is currently receive plan receive anticoagulant medication receive anticoagulant medication ( except equal less 150 mg aspirin daily overthecounter nonsteroidal antiinflammatory drug [ NSAIDs ] ) within 7 day injection AA4500</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>XIAFLEX</keyword>
	<keyword>XIAPEX</keyword>
	<keyword>Dupuytren 's disease</keyword>
	<keyword>contracture</keyword>
</DOC>